[Endocrine and osteological deficits in long time survivors after malignant haematological disorders].
Ivan
D
D
Bereich Endokrinologie & Diabetologie, Universitätsklinikum Giessen und Marburg. ivan@med.uni-marburg.de
Kann
P H
PH
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001827:Body Height / Q000187:drug effects / Q000528:radiation effects; D001847:Bone Diseases / Q000175:diagnosis / Q000209:etiology*; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D003131:Combined Modality Therapy; D004700:Endocrine System Diseases / Q000175:diagnosis / Q000209:etiology*; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D010025:Osteoradionecrosis / Q000175:diagnosis / Q000209:etiology; D012307:Risk Factors; D017741:Survivors
D000970:Antineoplastic Agents